Why PTC Therapeutics Shares Skyrocketed 20.6% Today

Why PTC Therapeutics Shares Skyrocketed 20.6% Today

Fool

Image source: PTC Therapeutics.

After competitor Sarepta Therapeutics (NASDAQ: SRPT) won early approval of Exondys 51, a drug for Duchenne muscular dystrophy (DMD), investors sent PTC Therapeutics (NASDAQ: PTCT) shares soaring 20.6% today.

Continue reading

view Fool